When was Replay founded?

Replay was founded in 2021 and raised its 1st funding round 1 year after it was founded.

Where is Replay located?

Replay is headquartered in San Diego, United States.

How many employees does Replay have?

As of Sep 30, 2026, the latest employee count at Replay is 30.

Is Replay a funded company?

Replay is a funded company, having raised a total of $55M across 2 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Jul 25, 2022.

When was the latest funding round of Replay?

Replay's latest funding was a $***** Grant (prize money) round on Nov 28, 2022, with participation from 1 investor.

Where does Replay rank among its competitors?

Replay ranks 62nd amongst 1398 active competitors, of which 294 are funded. It stands 8th in terms of total funding among its competitors. The most recent competitor to raise funding was Aspen Neuroscience, which secured $115M in Nov, 2025.

Who are the top competitors of Replay?

Replay's top competitors include Alnylam, Forge Biologics and Strand Therapeutics. Among them, Aspen Neuroscience secured the most recent funding round in November, 2025.

Replay - 2026 Company Profile, Team, Funding & Competitors

Company Details

Provider of genomic reprogramming platform for writing and delivering big DNA. It offers proprietary technology platforms, synHSV - a high payload capacity HSV vector able to deliver up to 30x the payload of AAV, uCell - a universal, renewable, off-the-shelf, genomically rewritten, hypoimmunogenic iPSC-derived cell source for regenerative medicine and cell therapy, DropSynth - a genome writing platform, LASR inference algorithm platform for rewriting proteins to optimize the functionality.

Website: replay.bio
Social
Email ID: *****@replay.bio

Key Metrics

Founded Year

2021

Location

San Diego, United States

Stage

Acquired

Total Funding

$55M in 2 rounds

Latest Funding Round

Grant (prize money), Nov 28, 2022, $*****

Investors

KKR & 7 more

Ranked

62^nd among 1398 active competitors

Employee Count

30 as on Sep 30, 2026

Similar Companies

Alnylam & 865 more

Exit Details

Acquired by LEO Pharma (Apr 30, 2026)

View Replay's full profile

Replay is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Reports
Replay Holdings, LLC CIN: 83-1807898 , United States, Active	Dec 31, 2020	-	13 (As on Dec 31, 2021)	-

Replay got acquired by LEO Pharma on Apr 30, 2026.

Click here to take a look at Replay's acquisition in detail

Replay has raised a total funding of $55M over 2 rounds. Its first funding round was on Jul 25, 2022. Its latest funding round was a Grant (prize money) round on Nov 28, 2022 for $*****. 1 investor participated in its latest round. Replay has 8 institutional investors.

Here is the list of recent funding rounds of Replay:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Nov 28, 2022	9253795	Grant (prize money)	9803605	1182641	6219303	7105256
Jul 25, 2022	1679694	Seed	9328549	5589589	KKR & 1 more	Artis Ventures & 4 more

Access funding benchmarks and valuations. Sign up today!

View details of Replay's funding rounds and investors

The founders of Replay are Adrian Woolfson, Nitin Kandhari, David Knipe and Ron Weiss. Lachlan MacKinnon is the CEO of Replay.

Here are the details of Replay's key team members:

Adrian Woolfson: Former Co-Founder of Replay.
Nitin Kandhari: Co-Founder of Replay.
David Knipe: Co-Founder of Replay.
Ron Weiss: Co-Founder of Replay.

View details of Replay's Founder profiles and Board Members

Replay's employee count trend

Replay has 30 employees as of Sep 26. Here is Replay's employee count trend over the years:

Uncover Replay's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Replay include Alnylam, Forge Biologics and Strand Therapeutics. Here is the list of Top 10 competitors of Replay, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Alnylam 2002, Cambridge (United States), Public	Developer of RNA interference-based therapeutics for multiple disorders	$17M	Colt Ventures, Atlas Venture & 14 others	81/100
2nd	Forge Biologics 2020, Columbus (United States), Acquired	Developer of gene therapeutic solutions for treating multiple diseases	$330M	RA Capital Management, Aisling Capital & 7 others	72/100
3rd	Strand Therapeutics 2017, Cambridge (United States), Series B	Provider of platform to deliver mRNA therapeutics for multi functional treatments	$256M	Kinnevik, Playground Global & 19 others	71/100
4th	Spark Therapeutics 2013, Philadelphia (United States), Acquired	Developer of gene therapy for rare diseases	$82.8M	Sofinnova Investments, Brookside Capital & 6 others	69/100
5th	Strand Life Sciences 2000, Bengaluru (India), Acquired	Provider of omics-based solutions for clinical genomics, systems biology, and drug discovery	$34.9M	Biomark Capital, WestBridge Capital & 92 others	69/100
6th	Ionis 1989, United States, Public	Developer of RNA-targeted medicines for various diseases	-	BB Biotech, Ojp & 1 others	69/100
7th	Stoke Therapeutics 2014, Bedford (United States), Public	Developer of antisense oligonucleotide drugs for treating inherited diseases by targeting RNA splicing	$131M	RTW Investments, Apple Tree Partners & 5 others	68/100
8th	Intellia Therapeutics 2014, Cambridge (United States), Public	Developer of genome editing therapeutics using CRISPR and Cas9 technology	$85M	Atlas Venture, Novartis & 10 others	68/100
9th	Dyne Therapeutics 2017, Cambridge (United States), Public	Developer of nucleic acid therapies for rare diseases	$166M	Atlas Venture, Logos & 5 others	67/100
10th	Aspen Neuroscience 2018, San Diego (United States), Series C	Provider of genomic-based personalised pluripotent stem cell therapy	$339M	Revelation Partners, Orbimed & 22 others	67/100
62nd	Replay 2021, San Diego (United States), Acquired	Provider of genomic reprogramming platform for writing and delivering big DNA	$55M	Lansdowne Partners, Artis Ventures & 6 others	55/100